Roche receives positive CHMP opinion for Gavreto ® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated w ith a RET inhibitor.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news